Zhongmou Therapeutics is a global clinical-stage biotechnology company focused on restoring vision for millions affected by blindness-causing ocular diseases. Leveraging 20+ years of pioneering gene therapy research, Zhongmou has advanced from lab research to clinical applications, delivering sight-restoring breakthroughs. The company utilizes a robust AAV vector platform and cutting-edge optogenetic therapies to develop a diverse product pipeline targeting significant unmet needs. Zhongmou's innovations include China's first gene therapy for retinal splitting and leading optogenetic therapies featuring photosensitive proteins, solidifying its leadership in the ophthalmic field. These groundbreaking therapies push the boundaries of science and aim to improve public health outcomes through advanced medical innovation.